NCT05388916View on ClinicalTrials.gov

A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

CompletedOBSERVATIONAL
Enrollment

42

Participants

Timeline

Start Date

September 8, 2022

Primary Completion Date

February 27, 2025

Study Completion Date

February 27, 2025

Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
OTHER

Cosentyx

Prospective observational cohort study. There is no treatment allocation. Patients administered Cosentyx by prescription will be enrolled.

Trial Locations (7)

100069

Novartis Investigative Site, Beijing

110003

Novartis Investigative Site, Shenyang

310009

Novartis Investigative Site, Hangzhou

450018

Novartis Investigative Site, Zhengzhou

510091

Novartis Investigative Site, Guangdong

710004

Novartis Investigative Site, Xian

050000

Novartis Investigative Site, Shijiazhuang

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY